首页 > 最新文献

European Endocrinology最新文献

英文 中文
ADA-EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes in an Afro-Asian Context: Broadening the Perspective. ADA-EASD 关于亚非背景下 2 型糖尿病患者高血糖管理的共识报告:拓宽视野。
Q2 Medicine Pub Date : 2023-11-01 Epub Date: 2023-04-21 DOI: 10.17925/EE.2023.19.2.1
Saptarshi Bhattacharya, Sanjay Kalra

The American Diabetes Association and the European Association for the Study of Diabetes consensus statement 2022 effectively captures the changing paradigm of modern diabetes care. As emphasized in the guidelines, a person-centered decision cycle focusing on preventing complications and improving quality of life is the driving principle behind modern diabetes management. Other notable features of the document are its emphasis on self-management education, therapeutic behaviour, sleep hygiene, nonalcoholic fatty liver disease and weight loss. Focus on individualization of care, social determinants of health, and ethnic variations are pertinent from an Afro-Asian perspective. The "language matters" section is a welcome addition that will help to overcome several barriers in diabetes care.

美国糖尿病协会和欧洲糖尿病研究协会的第 2022 号共识声明有效地捕捉到了现代糖尿病护理模式的变化。正如该指南所强调的那样,以人为本的决策周期侧重于预防并发症和提高生活质量,这是现代糖尿病管理的驱动原则。该文件的其他显著特点是强调自我管理教育、治疗行为、睡眠卫生、非酒精性脂肪肝和减肥。从非裔亚洲人的角度来看,对护理个性化、健康的社会决定因素和种族差异的关注很有针对性。语言问题 "部分是一个值得欢迎的新增内容,将有助于克服糖尿病护理中的一些障碍。
{"title":"ADA-EASD Consensus Report on the Management of Hyperglycaemia in Type 2 Diabetes in an Afro-Asian Context: Broadening the Perspective.","authors":"Saptarshi Bhattacharya, Sanjay Kalra","doi":"10.17925/EE.2023.19.2.1","DOIUrl":"10.17925/EE.2023.19.2.1","url":null,"abstract":"<p><p>The American Diabetes Association and the European Association for the Study of Diabetes consensus statement 2022 effectively captures the changing paradigm of modern diabetes care. As emphasized in the guidelines, a person-centered decision cycle focusing on preventing complications and improving quality of life is the driving principle behind modern diabetes management. Other notable features of the document are its emphasis on self-management education, therapeutic behaviour, sleep hygiene, nonalcoholic fatty liver disease and weight loss. Focus on individualization of care, social determinants of health, and ethnic variations are pertinent from an Afro-Asian perspective. The \"language matters\" section is a welcome addition that will help to overcome several barriers in diabetes care.</p>","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"1 1","pages":"4-6"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10769473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67586546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Profile and Factors Associated with Adverse Outcomes in Coronavirus Disease 2019-associated Mucormycosis: A Single-centre Study. 2019年冠状病毒病相关黏液瘤病的临床概况及不良后果相关因素:单中心研究
Q2 Medicine Pub Date : 2023-11-01 Epub Date: 2023-06-01 DOI: 10.17925/EE.2023.19.2.2
Krishna S Nair, Murali Alagesan, Dhanya Jose, Chidambaram Yoganathan, Rethinam Saravanan, Krishnasamy Karthikeyan, Karuppannasamy Divya, Dinesh Babu, Cyril Rajan, Joseph M Pappachan

Background: The coronavirus disease 2019 (COVID-19) pandemic was associated with an increased incidence of mucormycosis globally. However, the clinical pattern, epidemiologic features and risk factors for adverse outcomes are not well established. Methods: We performed a retrospective analysis of the data from patients hospitalized with proven mucormycosis between April 2021 and August 2021. Patients were managed with a multi-disciplinary approach involving medical, surgical, and comorbidity treatment. The clinical presentation, management details, complications and outcomes, including mortality, were reviewed from clinical records. Results: The mean age of presentation was 53.7 (± 11.8) years, and 88 (84.6%) were men. Of the 104 cases with COVID-19-associated mucormycosis, 97 (93.27%) patients had diabetes, and 80.8% had a haemoglobin A1C (HbA1c) of ≥6.4% at diagnosis. Seventy percent of diabetes cases experienced steroid-induced hyperglycaemia during treatment. Even with appropriate treatment, 17 (16.35%) patients died. High HbA1c and creatinine levels, presence of chronic kidney disease (CKD), need for intensive care unit admission, and orbital evisceration were the risk factors associated with high mortality on multivariate logistic regression analysis. Cox regression analysis revealed that the overall mortality increased by a factor of 12% with each 1 percentage point increase in HbA1c ≥6.4% (hazard ratio 1.12; 95% confidence interval 0.95- 1.31). The mortality risk was even higher when diabetes was associated with CKD (hazard ratio 1.82; 95% confidence interval 0.24-14.00). Conclusion: High HbA1c and creatinine levels, intensive care unit admission, CKD, and aggressive disease requiring orbital evisceration are the predictors of mortality in patients with COVID-19-associated mucormycosis. Patients with these risk factors should be managed more actively to reduce morbidity and mortality.

背景:冠状病毒病 2019(COVID-19)大流行与全球粘孢子菌病发病率上升有关。然而,其临床模式、流行病学特征和不良后果的风险因素尚未得到很好的确定。研究方法我们对 2021 年 4 月至 2021 年 8 月期间证实患有粘孢子菌病的住院患者数据进行了回顾性分析。患者接受了多学科治疗,包括内科、外科和合并症治疗。临床病历回顾了患者的临床表现、管理细节、并发症和结果,包括死亡率。研究结果平均发病年龄为 53.7 (± 11.8)岁,88 例(84.6%)为男性。在104例COVID-19相关粘液瘤病例中,97例(93.27%)患者患有糖尿病,80.8%的患者在确诊时血红蛋白A1C(HbA1c)≥6.4%。70%的糖尿病病例在治疗期间出现了类固醇引起的高血糖。即使接受了适当的治疗,仍有 17 例(16.35%)患者死亡。在多变量逻辑回归分析中,高 HbA1c 和肌酐水平、慢性肾脏病(CKD)、需要入住重症监护室和眼眶外翻是与高死亡率相关的风险因素。Cox 回归分析显示,HbA1c ≥6.4% 每增加 1 个百分点,总死亡率就会增加 12%(危险比 1.12;95% 置信区间 0.95-1.31)。当糖尿病伴有慢性肾脏病时,死亡风险更高(危险比 1.82;95% 置信区间 0.24-14.00)。结论高 HbA1c 和肌酐水平、入住重症监护室、慢性肾功能衰竭和需要切除眼眶的侵袭性疾病是 COVID-19 相关粘孢子菌病患者死亡的预测因素。有这些风险因素的患者应得到更积极的管理,以降低发病率和死亡率。
{"title":"Clinical Profile and Factors Associated with Adverse Outcomes in Coronavirus Disease 2019-associated Mucormycosis: A Single-centre Study.","authors":"Krishna S Nair, Murali Alagesan, Dhanya Jose, Chidambaram Yoganathan, Rethinam Saravanan, Krishnasamy Karthikeyan, Karuppannasamy Divya, Dinesh Babu, Cyril Rajan, Joseph M Pappachan","doi":"10.17925/EE.2023.19.2.2","DOIUrl":"10.17925/EE.2023.19.2.2","url":null,"abstract":"<p><p><b>Background</b>: The coronavirus disease 2019 (COVID-19) pandemic was associated with an increased incidence of mucormycosis globally. However, the clinical pattern, epidemiologic features and risk factors for adverse outcomes are not well established. <b>Methods</b>: We performed a retrospective analysis of the data from patients hospitalized with proven mucormycosis between April 2021 and August 2021. Patients were managed with a multi-disciplinary approach involving medical, surgical, and comorbidity treatment. The clinical presentation, management details, complications and outcomes, including mortality, were reviewed from clinical records. <b>Results</b>: The mean age of presentation was 53.7 (± 11.8) years, and 88 (84.6%) were men. Of the 104 cases with COVID-19-associated mucormycosis, 97 (93.27%) patients had diabetes, and 80.8% had a haemoglobin A1C (HbA1c) of ≥6.4% at diagnosis. Seventy percent of diabetes cases experienced steroid-induced hyperglycaemia during treatment. Even with appropriate treatment, 17 (16.35%) patients died. High HbA1c and creatinine levels, presence of chronic kidney disease (CKD), need for intensive care unit admission, and orbital evisceration were the risk factors associated with high mortality on multivariate logistic regression analysis. Cox regression analysis revealed that the overall mortality increased by a factor of 12% with each 1 percentage point increase in HbA1c ≥6.4% (hazard ratio 1.12; 95% confidence interval 0.95- 1.31). The mortality risk was even higher when diabetes was associated with CKD (hazard ratio 1.82; 95% confidence interval 0.24-14.00). <b>Conclusion</b>: High HbA1c and creatinine levels, intensive care unit admission, CKD, and aggressive disease requiring orbital evisceration are the predictors of mortality in patients with COVID-19-associated mucormycosis. Patients with these risk factors should be managed more actively to reduce morbidity and mortality.</p>","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"1 1","pages":"73-79"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10769467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67586580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What is Glycaemic Variability and which Pharmacological Treatment Options are Effective? A Narrative Review. 什么是血糖变异性,哪些药物治疗方案是有效的?叙述性评论。
Q2 Medicine Pub Date : 2023-07-01 Epub Date: 2023-07-07 DOI: 10.17925/EE.2023.19.2.4
Juan Miguel Huertas Cañas, Maria Alejandra Gomez Gutierrez, Andres Bedoya Ossa

Glycated haemoglobin is currently used for diagnosis and follow-up of diabetes mellitus. However, it has important limitations; as it only reflects the average glycaemia over the last 3 months, it does not allow the identification of crucial events, such as episodes of hypoglycaemia and hyperglycaemia. Strict control of hyperglycaemia can result in severe hypoglycaemia that can be life threatening and can have important sequelae. Recently, the concept of glycaemic variability has been developed to provide information about the magnitude of glycaemic excursions and the duration of these fluctuations. This new approach has the potential to improve outcomes, decrease the risk of hypoglycaemia, and decrease cardiovascular risk. This review describes the most commonly prescribed non-insulin anti-diabetic drugs for diabetes management, their mechanism of action, and the existing evidence about their effectiveness in improving glycaemic variability and diabetes control.

糖化血红蛋白目前用于糖尿病的诊断和随访。然而,它有重要的局限性;由于它仅反映过去3个月的平均血糖,因此不能识别关键事件,如低血糖和高血糖发作。严格控制高血糖会导致严重的低血糖,这可能危及生命,并可能有重要的后遗症。最近,血糖变异性的概念已经发展,以提供关于血糖偏离的幅度和这些波动的持续时间的信息。这种新方法有可能改善预后,降低低血糖的风险,并降低心血管风险。本文综述了糖尿病治疗中最常用的非胰岛素抗糖尿病药物,它们的作用机制,以及它们在改善血糖变异性和控制糖尿病方面的有效性的现有证据。
{"title":"What is Glycaemic Variability and which Pharmacological Treatment Options are Effective? A Narrative Review.","authors":"Juan Miguel Huertas Cañas, Maria Alejandra Gomez Gutierrez, Andres Bedoya Ossa","doi":"10.17925/EE.2023.19.2.4","DOIUrl":"10.17925/EE.2023.19.2.4","url":null,"abstract":"<p><p>Glycated haemoglobin is currently used for diagnosis and follow-up of diabetes mellitus. However, it has important limitations; as it only reflects the average glycaemia over the last 3 months, it does not allow the identification of crucial events, such as episodes of hypoglycaemia and hyperglycaemia. Strict control of hyperglycaemia can result in severe hypoglycaemia that can be life threatening and can have important sequelae. Recently, the concept of glycaemic variability has been developed to provide information about the magnitude of glycaemic excursions and the duration of these fluctuations. This new approach has the potential to improve outcomes, decrease the risk of hypoglycaemia, and decrease cardiovascular risk. This review describes the most commonly prescribed non-insulin anti-diabetic drugs for diabetes management, their mechanism of action, and the existing evidence about their effectiveness in improving glycaemic variability and diabetes control.</p>","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"1 1","pages":"16-21"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688563/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67586624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alarming Surge in Early-onset Type 2 Diabetes: A Global Catastrophe on the Horizon. 早发型2型糖尿病的惊人激增:一场即将到来的全球灾难。
Q2 Medicine Pub Date : 2023-07-01 Epub Date: 2023-07-13 DOI: 10.17925/EE.2023.19.2.5
Arefin Sadat

Diabetes poses a significant threat to public health. In the last 30 years, the worldwide incidence of type 2 diabetes mellitus (T2DM) has increased drastically among adolescents. Since the number of young people with T2DM is rising, it is anticipated that early-onset T2DM will become a common characteristic of the diabetes population in developed and developing nations. Current evidence suggests that β-cell function declines more rapidly in early-onset T2DM than in older-onset T2DM. In addition, early-onset T2DM appears to be associated with a greater risk of complications, comorbidities and mortality than type 1 diabetes mellitus. A stressful lifestyle, a shifted dietary habit and a lack of physical activity are cited as causes of early-onset T2DM. Early-onset T2DM is, therefore, an urgent public health concern requiring early prevention, efficient screening and prompt intervention. This article discusses the recent literature on the incidence, mortality, morbidity and risk variables of early-onset T2DM, and the current priorities and prospective directions.

糖尿病对公众健康构成重大威胁。在过去的30年里,全球青少年2型糖尿病(T2DM)的发病率急剧上升。由于年轻人患2型糖尿病的人数正在上升,预计早发性2型糖尿病将成为发达国家和发展中国家糖尿病人群的共同特征。目前的证据表明,β细胞功能在早发型T2DM中比在老发型T2DM中下降得更快。此外,与1型糖尿病相比,早发型2型糖尿病出现并发症、合并症和死亡率的风险更高。紧张的生活方式、改变的饮食习惯和缺乏体育锻炼被认为是导致早发型2型糖尿病的原因。因此,早发型2型糖尿病是一个迫切的公共卫生问题,需要早期预防、有效筛查和及时干预。本文讨论了最近关于早发性T2DM的发病率、死亡率、发病率和危险变量的文献,以及当前的重点和未来的发展方向。
{"title":"Alarming Surge in Early-onset Type 2 Diabetes: A Global Catastrophe on the Horizon.","authors":"Arefin Sadat","doi":"10.17925/EE.2023.19.2.5","DOIUrl":"10.17925/EE.2023.19.2.5","url":null,"abstract":"<p><p>Diabetes poses a significant threat to public health. In the last 30 years, the worldwide incidence of type 2 diabetes mellitus (T2DM) has increased drastically among adolescents. Since the number of young people with T2DM is rising, it is anticipated that early-onset T2DM will become a common characteristic of the diabetes population in developed and developing nations. Current evidence suggests that β-cell function declines more rapidly in early-onset T2DM than in older-onset T2DM. In addition, early-onset T2DM appears to be associated with a greater risk of complications, comorbidities and mortality than type 1 diabetes mellitus. A stressful lifestyle, a shifted dietary habit and a lack of physical activity are cited as causes of early-onset T2DM. Early-onset T2DM is, therefore, an urgent public health concern requiring early prevention, efficient screening and prompt intervention. This article discusses the recent literature on the incidence, mortality, morbidity and risk variables of early-onset T2DM, and the current priorities and prospective directions.</p>","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"1 1","pages":"7-8"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67586632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Parathyroid Carcinoma Presenting as Recurrent Primary Hyperparathyroidism and Neck Mass: A Case Report. 甲状旁腺癌表现为复发性原发性甲状旁腺功能亢进及颈部肿块1例。
Q2 Medicine Pub Date : 2023-07-01 Epub Date: 2023-07-11 DOI: 10.17925/EE.2023.19.2.6
Hiya Boro, Harish Sharma, Deepak Mittal, Mohit Pareek, Shilpa Chugh, Mohar Singh Jakhar, Neeraj Nagar, Lovekesh Bhatia, Sanjay Saini, Vashishth Joshi, Sahil Vaid, Velmurugan Mannar, Lakshmi Nagendra, Mazhar Dalvi, Vikash Bundela

Parathyroid carcinoma is a rare endocrine neoplasm that accounts for <1% of cases of primary hyperparathyroidism. The management of parathyroid carcinoma is a challenge due to the high rate of local recurrence of the tumour. We report the case of a middle-aged north Indian woman who presented with recurrent primary hyperparathyroidism due to parathyroid carcinoma. She presented with a recurrent palpable hard neck mass and underwent radical dissection of the neck six times. At the time of writing this report, she was referred for external beam radiotherapy to the neck. Parathyroid carcinoma is a rare malignancy with an indolent but tenacious course. Complete resection at the time of initial surgery determines the prognosis of the neoplasm. Chemotherapy and radiotherapy are usually ineffective. Hypercalcaemia needs to be aggressively managed. A multidisciplinary team is required to effectively manage parathyroid carcinoma.

甲状旁腺癌是一种罕见的内分泌肿瘤
{"title":"Parathyroid Carcinoma Presenting as Recurrent Primary Hyperparathyroidism and Neck Mass: A Case Report.","authors":"Hiya Boro, Harish Sharma, Deepak Mittal, Mohit Pareek, Shilpa Chugh, Mohar Singh Jakhar, Neeraj Nagar, Lovekesh Bhatia, Sanjay Saini, Vashishth Joshi, Sahil Vaid, Velmurugan Mannar, Lakshmi Nagendra, Mazhar Dalvi, Vikash Bundela","doi":"10.17925/EE.2023.19.2.6","DOIUrl":"10.17925/EE.2023.19.2.6","url":null,"abstract":"<p><p>Parathyroid carcinoma is a rare endocrine neoplasm that accounts for <1% of cases of primary hyperparathyroidism. The management of parathyroid carcinoma is a challenge due to the high rate of local recurrence of the tumour. We report the case of a middle-aged north Indian woman who presented with recurrent primary hyperparathyroidism due to parathyroid carcinoma. She presented with a recurrent palpable hard neck mass and underwent radical dissection of the neck six times. At the time of writing this report, she was referred for external beam radiotherapy to the neck. Parathyroid carcinoma is a rare malignancy with an indolent but tenacious course. Complete resection at the time of initial surgery determines the prognosis of the neoplasm. Chemotherapy and radiotherapy are usually ineffective. Hypercalcaemia needs to be aggressively managed. A multidisciplinary team is required to effectively manage parathyroid carcinoma.</p>","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"1 1","pages":"80-85"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10688562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67586674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Teplizumab in Type 1 Diabetes Mellitus: An Updated Review Teplizumab治疗1型糖尿病:最新综述
Q2 Medicine Pub Date : 2023-01-01 DOI: 10.17925/ee.2023.19.2.7
Simran Thakkar, Aditi Chopra, Lakshmi Nagendra, Sanjay Kalra, Saptarshi Bhattacharya
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune condition characterized by the irreversible destruction of the β cells of the pancreas, which leads to a lifelong dependency on exogenous insulin. Despite the advancements in insulin delivery methods, the suboptimal outcomes of these methods have triggered the search for therapies that may prevent or reverse the disease. Given the autoimmune aetiology of T1DM, therapies counteracting the immune-mediated destruction of the β-cells are the obvious target. Although several treatment strategies have been attempted to target cellular, humoral and innate immunity, very few have had a clinically meaningful impact. Of all the available immunomodulatory agents, cluster of differentiation (CD) 3 antibodies have exhibited the most promising preclinical and clinical results. Muromonab-CD3, which also happened to be a murine CD3 antibody, was the first monoclonal antibody approved for clinical use and was primarily indicated for graft rejection. The adverse effects associated with muromonab-CD3 led to its withdrawal. Teplizumab, a newer CD3 antibody, has a better side-effect profile because of its humanized nature and non-Fc- receptor- binding domain. In November 2022, teplizumab became the first immunomodulatory agent to be licensed by the US Food and Drug Administration for delaying the onset of T1DM in high-risk adults and children over 8 years old. The mechanism seems to be enhancing regulatory T-cell activity and promoting immune tolerance. This article reviews the mechanism of action and the clinical trials of teplizumab in individuals with T1DM or at risk of developing the disease.
1型糖尿病(T1DM)是一种慢性自身免疫性疾病,其特征是胰腺β细胞的不可逆破坏,导致终生依赖外源性胰岛素。尽管胰岛素输送方法取得了进步,但这些方法的次优结果引发了对可能预防或逆转该疾病的治疗方法的研究。鉴于T1DM的自身免疫性病因,对抗免疫介导的β细胞破坏的治疗是明显的目标。虽然已经尝试了几种针对细胞、体液和先天免疫的治疗策略,但很少有临床意义的影响。在所有可用的免疫调节剂中,分化簇(cd3)抗体已显示出最有希望的临床前和临床结果。Muromonab-CD3也是一种小鼠CD3抗体,是第一个被批准用于临床的单克隆抗体,主要用于移植排斥反应。与muromonab-CD3相关的副作用导致其停药。Teplizumab是一种较新的CD3抗体,由于其人源性和非fc受体结合结构域,具有更好的副作用。2022年11月,teplizumab成为第一个获得美国食品和药物管理局许可的免疫调节剂,用于延迟高危成人和8岁以上儿童的T1DM发病。其机制似乎是增强调节性t细胞活性和促进免疫耐受。本文综述了替普利单抗在T1DM或有发病风险个体中的作用机制和临床试验。
{"title":"Teplizumab in Type 1 Diabetes Mellitus: An Updated Review","authors":"Simran Thakkar, Aditi Chopra, Lakshmi Nagendra, Sanjay Kalra, Saptarshi Bhattacharya","doi":"10.17925/ee.2023.19.2.7","DOIUrl":"https://doi.org/10.17925/ee.2023.19.2.7","url":null,"abstract":"Type 1 diabetes mellitus (T1DM) is a chronic autoimmune condition characterized by the irreversible destruction of the β cells of the pancreas, which leads to a lifelong dependency on exogenous insulin. Despite the advancements in insulin delivery methods, the suboptimal outcomes of these methods have triggered the search for therapies that may prevent or reverse the disease. Given the autoimmune aetiology of T1DM, therapies counteracting the immune-mediated destruction of the β-cells are the obvious target. Although several treatment strategies have been attempted to target cellular, humoral and innate immunity, very few have had a clinically meaningful impact. Of all the available immunomodulatory agents, cluster of differentiation (CD) 3 antibodies have exhibited the most promising preclinical and clinical results. Muromonab-CD3, which also happened to be a murine CD3 antibody, was the first monoclonal antibody approved for clinical use and was primarily indicated for graft rejection. The adverse effects associated with muromonab-CD3 led to its withdrawal. Teplizumab, a newer CD3 antibody, has a better side-effect profile because of its humanized nature and non-Fc- receptor- binding domain. In November 2022, teplizumab became the first immunomodulatory agent to be licensed by the US Food and Drug Administration for delaying the onset of T1DM in high-risk adults and children over 8 years old. The mechanism seems to be enhancing regulatory T-cell activity and promoting immune tolerance. This article reviews the mechanism of action and the clinical trials of teplizumab in individuals with T1DM or at risk of developing the disease.","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"312 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136367236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Global Liver Institute "Liver Health is Public Health" Initiative 全球肝脏研究所“肝脏健康是公共健康”倡议
Q2 Medicine Pub Date : 2023-01-01 DOI: 10.17925/ee.2023.19.2.3
D. Cryer

{"title":"The Global Liver Institute \"Liver Health is Public Health\" Initiative","authors":"D. Cryer","doi":"10.17925/ee.2023.19.2.3","DOIUrl":"https://doi.org/10.17925/ee.2023.19.2.3","url":null,"abstract":"<p />","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67586592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Enhanced External Counter-pulsation Therapy on Glycaemic Control in People With Prediabetes and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis 强化外抗搏动治疗对糖尿病前期和2型糖尿病患者血糖控制的影响:一项系统综述和荟萃分析
Q2 Medicine Pub Date : 2023-01-01 DOI: 10.17925/ee.2023.19.2.8
Lakshmi Nagendra, Deep Dutta, Meha Sharma, Harish Bg
Background: Enhanced external counter-pulsation (EECP) therapy is approved for refractory angina in coronary artery disease (CAD). EECP is being explored as a treatment modality in type 2 diabetes mellitus (T2DM). Methods: The Embase, Web of Science, Cochrane Library, MEDLINE (PubMed), ClinicaltTrials. gov, CNKI database, Clinical Trials Registry-India (CTRI), and Google Scholar databases were searched for randomized controlled trials (RCTs) involving patients receiving EECP therapy in the intervention arm. The primary outcome was the changes in glycated haemoglobin (HbA1c). The secondary outcomes were the changes in blood glucose parameters, inflammatory markers and any adverse events. Results: Data from 3 RCTs involving 71 people with T2DM/prediabetes was analysed to find out the impact of EECP therapy compared with placebo. As compared with placebo, patients receiving EECP had significantly lower HbA1C immediately after completion of therapy (mean difference [MD] -0.70%, 95% confidence interval (CI) -0.95. -0.45;p<0.00001), at 2–4 weeks post completion of therapy (MD -1.04%, 95%CI -1.32. -0.77; p<0.00001) and 7–12 weeks after therapy completion (MD -0.98%, 95% CI -1.22, -0.74; p<0.00001). EECP therapy was well tolerated without any increased side effects (risk ratio 2.36, 95% CI 0.11–52.41; p=0.59. Conclusion: EECP therapy is effective in blood glucose and pressure lowering over at least 7–12 weeks of therapy completion. Blood glucose and pressure should be monitored with suitable modulation of drug doses to prevent hypoglycaemia and hypotension in patients with angina undergoing EECP therapy. The PROSPERO registration number is CRD42023434533
背景:增强体外反搏(EECP)疗法被批准用于治疗冠状动脉疾病(CAD)难治性心绞痛。EECP作为2型糖尿病(T2DM)的一种治疗方式正在被探索。方法:Embase, Web of Science, Cochrane Library, MEDLINE (PubMed), ClinicaltTrials。我们检索了在干预组中接受EECP治疗的患者的随机对照试验(rct),检索了CNKI数据库、Clinical Trials Registry-India (CTRI)和Google Scholar数据库。主要终点是糖化血红蛋白(HbA1c)的变化。次要结果是血糖参数、炎症标志物和任何不良事件的变化。结果:我们分析了3项随机对照试验的数据,涉及71例T2DM/前驱糖尿病患者,以找出与安慰剂相比,EECP治疗的影响。与安慰剂相比,接受EECP的患者在治疗完成后立即的HbA1C显著降低(平均差[MD] -0.70%, 95%可信区间(CI) -0.95)。-0.45;p<0.00001),在治疗完成后2-4周(MD -1.04%, 95%CI -1.32)。-0.77;p<0.00001)和治疗完成后7-12周(MD -0.98%, 95% CI -1.22, -0.74;术中,0.00001)。EECP治疗耐受性良好,无副作用增加(风险比2.36,95% CI 0.11-52.41;p = 0.59。结论:EECP治疗在治疗完成后至少7-12周内血糖和血压降低是有效的。应监测血糖和血压,适当调节药物剂量,以防止心绞痛患者接受EECP治疗时出现低血糖和低血压。普洛斯彼罗注册号是CRD42023434533
{"title":"Impact of Enhanced External Counter-pulsation Therapy on Glycaemic Control in People With Prediabetes and Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis","authors":"Lakshmi Nagendra, Deep Dutta, Meha Sharma, Harish Bg","doi":"10.17925/ee.2023.19.2.8","DOIUrl":"https://doi.org/10.17925/ee.2023.19.2.8","url":null,"abstract":"<bold>Background:</bold> Enhanced external counter-pulsation (EECP) therapy is approved for refractory angina in coronary artery disease (CAD). EECP is being explored as a treatment modality in type 2 diabetes mellitus (T2DM). <bold>Methods:</bold> The Embase, Web of Science, Cochrane Library, MEDLINE (PubMed), ClinicaltTrials. gov, CNKI database, Clinical Trials Registry-India (CTRI), and Google Scholar databases were searched for randomized controlled trials (RCTs) involving patients receiving EECP therapy in the intervention arm. The primary outcome was the changes in glycated haemoglobin (HbA1c). The secondary outcomes were the changes in blood glucose parameters, inflammatory markers and any adverse events. <bold>Results:</bold> Data from 3 RCTs involving 71 people with T2DM/prediabetes was analysed to find out the impact of EECP therapy compared with placebo. As compared with placebo, patients receiving EECP had significantly lower HbA1C immediately after completion of therapy (mean difference [MD] -0.70%, 95% confidence interval (CI) -0.95. -0.45;p<0.00001), at 2–4 weeks post completion of therapy (MD -1.04%, 95%CI -1.32. -0.77; p<0.00001) and 7–12 weeks after therapy completion (MD -0.98%, 95% CI -1.22, -0.74; p<0.00001). EECP therapy was well tolerated without any increased side effects (risk ratio 2.36, 95% CI 0.11–52.41; p=0.59. <bold>Conclusion:</bold> EECP therapy is effective in blood glucose and pressure lowering over at least 7–12 weeks of therapy completion. Blood glucose and pressure should be monitored with suitable modulation of drug doses to prevent hypoglycaemia and hypotension in patients with angina undergoing EECP therapy. The PROSPERO registration number is CRD42023434533","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136373987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Update on Alopecia and its Association With Thyroid Autoimmune Diseases 脱发及其与甲状腺自身免疫性疾病关系的研究进展
Q2 Medicine Pub Date : 2023-01-01 DOI: 10.17925/ee.2023.19.2.10
Doaa Aboalola, Sihem Aouabdi, Majed Ramadan, Tariq Alghamdi, Mona Alsolami, Dalal Malibari, Rawiah Alsiary
Alopecia is comorbid with several illnesses, including various autoimmune conditions such as thyroid disease. Leukocyte-mediated inflammation of hair follicles in alopecia was first described over a century ago. However, the high prevalence of the role of thyroid autoimmune disease in the pathogenesis of alopecia has only recently come to light, together with a strong association between the two. Therefore, this review focuses on articles published between 2011 and 2022 on alopecia's association with thyroid autoimmune disease, and the mechanism behind it. In addition, it highlights the link between alopecia and thyroid cancer, as patients with alopecia have increased risk of thyroid cancer. In conclusion, this comprehensive, focused, scoping review will serve as a reference highlighting recent information on alopecia, exploring its association with thyroid autoimmune diseases.
脱发与多种疾病合并症,包括各种自身免疫性疾病,如甲状腺疾病。白细胞介导的脱发毛囊炎症在一个多世纪前首次被描述。然而,甲状腺自身免疫性疾病在脱发发病机制中的高患病率直到最近才被发现,两者之间也有很强的联系。因此,本综述的重点是2011年至2022年间发表的关于脱发与甲状腺自身免疫性疾病的关系及其背后机制的文章。此外,它还强调了脱发和甲状腺癌之间的联系,因为脱发患者患甲状腺癌的风险增加。总之,这篇全面的、有重点的、范围广泛的综述将作为一个参考,强调脱发的最新信息,探讨其与甲状腺自身免疫性疾病的关系。
{"title":"An Update on Alopecia and its Association With Thyroid Autoimmune Diseases","authors":"Doaa Aboalola, Sihem Aouabdi, Majed Ramadan, Tariq Alghamdi, Mona Alsolami, Dalal Malibari, Rawiah Alsiary","doi":"10.17925/ee.2023.19.2.10","DOIUrl":"https://doi.org/10.17925/ee.2023.19.2.10","url":null,"abstract":"Alopecia is comorbid with several illnesses, including various autoimmune conditions such as thyroid disease. Leukocyte-mediated inflammation of hair follicles in alopecia was first described over a century ago. However, the high prevalence of the role of thyroid autoimmune disease in the pathogenesis of alopecia has only recently come to light, together with a strong association between the two. Therefore, this review focuses on articles published between 2011 and 2022 on alopecia's association with thyroid autoimmune disease, and the mechanism behind it. In addition, it highlights the link between alopecia and thyroid cancer, as patients with alopecia have increased risk of thyroid cancer. In conclusion, this comprehensive, focused, scoping review will serve as a reference highlighting recent information on alopecia, exploring its association with thyroid autoimmune diseases.","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"134 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136374238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Are Prepubertal Gynaecomastia and Premature Thelarche Linked to Topical Lavender and Tea Tree Oil Use? 外用薰衣草和茶树精油是否与青春期前女性乳房发育和乳房发育过早有关?
Q2 Medicine Pub Date : 2023-01-01 DOI: 10.17925/ee.2023.19.2.9
Elsa W Braunstein, Glenn D Braunstein
Various studies, conducted since 2007, have reported a total of eight boys with prepubertal gynaecomastia and four girls with premature thelarche following exposure to lavender and/or tree tea oil. All patients experienced regression of the breast tissue after they stopped using these oils. Both of these essential oils, and several of their constituents, have oestrogenic and antiandrogenic activity in vitro. However, limited dermal penetration of some of the components means that the in vitro findings cannot be extrapolated to the in vivo situation. There are unanswered questions as to how much lavender or tea tree oil was actually present in the skincare products used by the children and a lack of information about exposure to other agents. Furthermore, since both prepubertal gynaecomastia and premature thelarche often spontaneously regress, it cannot be concluded that the use of lavender and/or tree tea oil is the cause of the gynaecomastia and thelarche in these children.
自2007年以来进行的各种研究报告称,在接触薰衣草和/或树茶油后,共有8名男孩患有青春期前妇科乳房发育症,4名女孩患有早产儿。所有患者在停止使用这些精油后,乳房组织都出现了退化。这两种精油及其成分在体外都具有雌激素和抗雄激素活性。然而,一些成分的皮肤渗透有限,这意味着体外的研究结果不能推断到体内的情况。至于儿童使用的护肤品中究竟含有多少薰衣草或茶树油,以及缺乏其他物质暴露的信息,目前还没有答案。此外,由于青春期前的女性乳房发育和过早的乳房发育通常会自行消退,因此不能断定使用薰衣草和/或树茶油是这些儿童的女性乳房发育和乳房发育的原因。
{"title":"Are Prepubertal Gynaecomastia and Premature Thelarche Linked to Topical Lavender and Tea Tree Oil Use?","authors":"Elsa W Braunstein, Glenn D Braunstein","doi":"10.17925/ee.2023.19.2.9","DOIUrl":"https://doi.org/10.17925/ee.2023.19.2.9","url":null,"abstract":"Various studies, conducted since 2007, have reported a total of eight boys with prepubertal gynaecomastia and four girls with premature thelarche following exposure to lavender and/or tree tea oil. All patients experienced regression of the breast tissue after they stopped using these oils. Both of these essential oils, and several of their constituents, have oestrogenic and antiandrogenic activity <italic>in vitro</italic>. However, limited dermal penetration of some of the components means that the <italic>in vitro</italic> findings cannot be extrapolated to the <italic>in vivo</italic> situation. There are unanswered questions as to how much lavender or tea tree oil was actually present in the skincare products used by the children and a lack of information about exposure to other agents. Furthermore, since both prepubertal gynaecomastia and premature thelarche often spontaneously regress, it cannot be concluded that the use of lavender and/or tree tea oil is the cause of the gynaecomastia and thelarche in these children.","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136374233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European Endocrinology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1